SBIR-STTR Award

An Injectable Biocompatible Hydrogel Nucleus Pulposus Replacement
Award last edited on: 6/7/11

Sponsored Program
SBIR
Awarding Agency
NIH : NIAMS
Total Award Amount
$76,738
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Gavin J Braithwaite

Company Information

Cambridge Polymer Group Inc (AKA: CPG)

56 Roland Street Suite 310
Boston, MA 02129
   (617) 629-4400
   info@campoly.com
   www.campoly.com
Location: Single
Congr. District: 07
County: Suffolk

Phase I

Contract Number: 1R43AR056892-01A1
Start Date: 8/1/09    Completed: 10/31/10
Phase I year
2009
Phase I Amount
$76,738
Lower back pain affects over 65 million people in the US alone, costing an estimated $100B annually. About 12 million of these cases arise from degeneration of the intervertebral disc (IVD) through trauma or natural aging. Additionally, disc degeneration results in compromised biomechanics with frequent progression to disrupted spinal dynamics, osteoarthritis and spinal instability. Many patients initially respond to conservative treatments such as anti-inflammatory medication but a significant number stop responding within a short period of time, at which point their main treatment option today is invasive surgery. Although commonly prescribed, moderately invasive surgical solutions such as discectomy and laminectomy, and more invasive solutions such as intervertebral fusion and total disc replacement have important problems and uncertainties surrounding their use. Clearly, a gap exists between marginally effective conservative treatments and invasive interventions. A solution is needed that can be applied minimally invasively while also directly addressing the root cause of the problem and allowing restoration of the biomechanics of an affected motion segment. This proposal describes the continued development of a suitable material to replace the nucleus pulposus of a degenerating disc, thereby restoring disc height and natural disc function. The existing principle technology is a novel method that forms a hydrogel from a liquid without a chemical reaction. Our specific aims will address the following requirements for an injectable poly(vinyl alcohol) (PVA) system as a nucleus pulposus (NP) replacement: (i) to exist as a liquid pre-gel that can be injected safely through an narrow gauge needle; (ii) to gel at body temperature and environment within minutes; (iii) to be space-filling and resist extrusion from annular tears, (iv) to survive at least 1 million cycles of dynamic loading with a peak load of 3 kN; and (v) be revisable to another treatment such as NP replacement, fusion or total disc replacement. To achieve this objective, we divide the proposed work into three Specific Aims: Specific Aim 1: We will investigate the effects of concentration, molecular weight, radiopacification and sterilization on the gelation kinetics and mechanical properties of a set of suitable hydrogels. Specific Aim 2: We will use a static extrusion model to screen the optimal hydrogel formulations developed in SA1, after gamma sterilization. Those formulations that pass the static extrusion will be subjected to dynamic extrusion for 100 thousand cycles. Specific Aim 3: We will use a simple IVD model under development that will allow the chosen formulation to be subjected to 1 million cycle fatigue testing of the material in physiologically relevant loading regimes. In addition, the successful formulations will also be fatigued in an IVD model with a deliberate annular defect. In addition, porcine Functional Spine Units (FSUs) will be tested to obtain early insight into changes in biomechanics due to the proposed procedure.

Public Health Relevance:
Chronic lower back pain, which afflicts 70% of the population at some point in their lives and costs the U.S. economy billions of dollars per year in worker's compensation and lost productivity, is often associated with degeneration of the intervertebral disc in the spine. The only treatment options available today are either pain medication or invasive surgical procedures involving joint fusion or total disc replacement. The research proposed here will further develop an innovative injectable hydrogel material that can replace or augment the existing intervertebral disc nucleus, and will hence restore the natural biomechanics of the joint and prevent or delay further degeneration of the spine.

Public Health Relevance Statement:
Project Narrative Chronic lower back pain, which afflicts 70% of the population at some point in their lives and costs the U.S. economy billions of dollars per year in worker's compensation and lost productivity, is often associated with degeneration of the intervertebral disc in the spine. The only treatment options available today are either pain medication or invasive surgical procedures involving joint fusion or total disc replacement. The research proposed here will further develop an innovative injectable hydrogel material that can replace or augment the existing intervertebral disc nucleus, and will hence restore the natural biomechanics of the joint and prevent or delay further degeneration of the spine.

Project Terms:
Address; Affect; Aging; Alcohols; Analgesic Agents; Analgesic Drugs; Analgesic Preparation; Analgesics; Anodynes; Anti-Inflammatories; Anti-Inflammatory Agents; Anti-inflammatory; Antiinflammatories; Antiinflammatory Agents; Antinociceptive Agents; Antinociceptive Drugs; Arthritis, Degenerative; Articulation; Barium Sulfate; Biocompatible; Biomechanics; Body Temperature; Cell Nucleus; Chemical Class, Alcohol; Chemistry; Chronic low back pain; Crystallization; Defect; Degenerative polyarthritis; Development; Drug Formulations; Drugs; Environment; Family suidae; Fatigue; Formulation; Formulations, Drug; Frequencies (time pattern); Frequency; Gait; Gel; Height; Hydrogels; Hydrogen Oxide; In Situ; In Vitro; Injectable; Intervention; Intervention Strategies; Intervertebral Disc Degenerative Disease; Intervertebral Disc Degenerative Disorder; Intervertebral Disk; Intervertebral disc structure; Joints; Kinetic; Kinetics; Lack of Energy; Laminectomy; Liquid substance; Living Costs; Load-Bearing; Loadbearing; Low Back Ache; Low Back Pain; Low Backache; Lumbago; Materials Testing; Measures; Mechanics; Medical Device; Medication; Methods; Modeling; Molecular Weight; Motion; Needles; Nerve; Nervous; Nucleus; Operation; Operative Procedures; Operative Surgical Procedures; Osteoarthritis; Osteoarthrosis; Outcome; Patients; Pharmaceutic Preparations; Pharmaceutical Preparations; Phase; Pigs; Plant Roots; Population; Procedures; Process; Productivity; Property; Property, LOINC Axis 2; Research; SBIR; SBIRS (R43/44); Science of Chemistry; Senescence; Simulate; Small Business Innovation Research; Small Business Innovation Research Grant; Solutions; Solvents; Sound; Sound - physical agent; Spinal; Spinal Column; Spine; Sterility; Sterilization; Sterilization for infection control; Structure; Suidae; Sulfuric acid, barium salt (1[{..}]1); Surgical; Surgical Interventions; Surgical Procedure; Swelling; Swine; System; System, LOINC Axis 4; Technology; Temperature; Testing; Time; Trauma; Uncertainty; Vertebral column; Water; Weight-Bearing; Weight-Bearing state; Weightbearing; Work; Workers' Compensation; Workmans Compensation; Workmen's Compensation; Workmens Compensation; analgesia; analog; aqueous; backbone; base; chemical reaction; cost; cross-link; crosslink; degenerative joint disease; doubt; drug/agent; experiment; experimental research; experimental study; fluid; hypertrophic arthritis; in vivo; innovate; innovation; innovative; insight; interventional strategy; intervertebral disk degeneration; liquid; minimally invasive; novel; nucleus pulposus; particle; porcine; prevent; preventing; public health relevance; research study; restoration; root; senescent; sound; sterile; suid; surgery

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----